• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment.PMID:37690934 | DOI:10.1016/j.urolonc.2023.08.012
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Aziz Hakk ı Civriz Kerem Teke Enes Malik Akdas Ozdal Dillioglugil Cigdem Vural Busra Yaprak Bayrak Source Type: research

Emergencies in cancer immunotherapy
CONCLUSIONS: Even emergencies are manageable if we know the most important side effects and the therapeutic options. Immune-mediated side effects are of particular importance because they can affect any organ system. However, as long as we consider the possibility of toxicity from checkpoint inhibitors when the patient presents with symptoms, most side effects are easy to treat and therefore manageable.PMID:37607581 | DOI:10.1055/a-2128-4849
Source: Aktuelle Urologie - August 22, 2023 Category: Urology & Nephrology Authors: Analena Handke Thomas Hilser Martin B ögemann Katrin Schlack Viktor Gr ünwald Source Type: research

Lower limb arterial thrombosis in  an adult with membranous glomerulonephritis
Clin Nephrol. 2023 Aug 7. doi: 10.5414/CN111046. Online ahead of print.ABSTRACTMassive proteinuria and hypoalbuminemia are potential risk factors in thromboembolic complications. Venous thrombosis is a frequent complication of thromboembolism in patients with membranous glomerulonephritis, while arterial thrombosis is much less reported. A 35-year-old man presented with nephrotic syndrome and osteofascial compartment syndrome in the right lower limb due to arterial thrombosis. The biopsy findings were consistent with those of stage 2 membranous nephropathy. After immunotherapy (steroids and cyclosporine), the massive prote...
Source: Clinical Nephrology - August 7, 2023 Category: Urology & Nephrology Authors: Kunxiao Zhao Lin Ruan Zheli Niu Qiongzhen Lin Source Type: research

Antibody-drug conjugates for urothelial carcinoma
Urol Oncol. 2023 Jul 5:S1078-1439(23)00219-3. doi: 10.1016/j.urolonc.2023.06.006. Online ahead of print.ABSTRACTThe standard of care for advanced urothelial carcinoma includes platinum chemotherapy and immunotherapy. Antibody-drug conjugates (ADCs), originally developed for hematologic malignancies, involve potent cytotoxic agents linked to antibodies that recognize tumor-specific antigens; this rational drug design allows for more on-target efficacy, while mitigating systemic toxicity. Herein, we review the emerging landscape of ADCs in urothelial carcinoma. The anti-Nectin-4 ADC enfortumab vedotin has demonstrated effica...
Source: Urologic Oncology - July 7, 2023 Category: Urology & Nephrology Authors: Joseph Thomas Michael Sun Ted Getz Benedict Ho Jones T Nauseef Scott T Tagawa Source Type: research

Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery
CONCLUSIONS: Nephrectomy is associated with an increase in cytolytic antigen-primed CD8+ T-cells and specific PBMC profile changes. Further studies are warranted to ascertain the role surgery may have in the restoration of anti-tumor immunity.PMID:37414595 | DOI:10.1016/j.urolonc.2023.05.009
Source: Urologic Oncology - July 6, 2023 Category: Urology & Nephrology Authors: Rodrigo Rodrigues Pessoa Henan Zhang Andrew Zganjar Reza Nabavizadeh Vignesh T Packiam Christine M Lohse John C Cheville Lance C Pagliaro Brian A Costello Stephen A Boorjian R Houston Thompson Fabrice Lucien Haidong Dong Bradley C Leibovich Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20